abs187.txt	a	hallmark	of	advanced	tumors	is	a	switch	to	aerobic	glycolysis	that	is	readilymeasured	by	[18f]-2-fluoro-2-deoxy-d-glucose	positron	emission	tomography(18f-fdg	pet)	imaging		co-mutations	in	the	kras	proto-oncogene	and	the	lkb1	tumorsuppressor	gene	are	frequent	events	in	lung	cancer	that	drive	hypermetabolic	glycolytic	tumor	growth		a	critical	pathway	regulating	the	growth	and	metabolismof	these	tumors	is	the	mechanistic	target	of	the	rapamycin	(mtor)	pathway		whichcan	be	effectively	targeted	using	selective	catalytic	mtor	kinase	inhibitors		themtor	inhibitor	mln0128	suppresses	glycolysis	in	mice	bearing	tumors	with	kras	andlkb1	co-mutations		referred	to	as	kl	mice		the	therapy	response	in	kl	mice	isfirst	measured	by	18f-fdg	pet	and	computed	tomography	(ct)	imaging	before	andafter	the	delivery	of	mln0128		by	utilizing	18f-fdg	pet/ct		researchers	are	ableto	measure	dynamic	changes	in	the	glucose	metabolism	in	genetically	engineeredmouse	models	(gemms)	of	lung	cancer	following	a	therapeutic	intervention	withtargeted	therapies		this	is	followed	by	ex	vivo	autoradiography	and	aquantitative	immunohistochemical	(qihc)	analysis	using	morphometric	software		theuse	of	qihc	enables	the	detection	and	quantification	of	distinct	changes	in	thebiomarker	profiles	following	treatment	as	well	as	the	characterization	ofdistinct	tumor	pathologies		the	coupling	of	pet	imaging	to	quantitative	histologyis	an	effective	strategy	to	identify	metabolic	and	therapeutic	responses	in	vivoin	mouse	models	of	disease	
